KR20070062007A - Anti-ulcer composition containing fermented extract of saccharified rice or glutinous rice and preparation method thereof - Google Patents

Abstract

An anti-ulcer composition comprising the fermented extract of saccharified rice or glutinous rice and a preparation method thereof are provided to prevent and treat ulcer, inhibit growth of Helicobacter pylori, and enhance safety of use by using natural products. The anti-ulcer composition comprises the fermented extract of saccharified rice or glutinous rice which is prepared by saccharifying the rice or glutinous rice with a saccharifying enzyme and fermenting the saccharified rice or glutinous rice by a lactic acid bacterium or a yeast. The saccharifying enzyme is koji, alpha-amylase or glucoamylase; the lactic acid bacterium is Lactobacillus rhamnosus, Lactobacillus sakei, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus delbruekii, Lactobacillus johnsonii, Streptococcus thermophilus, Streptococcus pythium, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Pediococcus pentosaceus or Leuconostoc mesenteroides; and the yeast is Saccharomyces cerevisiae, Saccharomyces sakei or Xanthophyllomyces dendrorhous. The preparation method of the anti-ulcer composition comprises the steps of: (a) saccharifying the rice or glutinous rice with the saccharifying enzyme; (b) and fermenting the saccharified product by the lactic acid bacterium or yeast.

Description

Anti-ulcer composition containing fermented broth of rice or glutinous rice glycosylate and method for preparing the anti-ulcer composition containing fermented extract of saccharified rice or glutinous rice and preparation method

1 is a diagram showing the ulceration index according to the fermentation strain of fermentation broth of glutinous rice sugars prepared by the method of the present invention.

Figure 2 is an illustration of the anti-helicobacter activity according to the fermentation strain of fermentation broth of glutinous rice sugars prepared by the method of the present invention.

Description of the main parts of the drawing

1: control group (untreated group)

2: Lactobacillus rhamnosus fermentation broth

3: Saccharomyccs ( Saccharomyccs) cerevisiae ) fermentation broth

4: Lactobacillus four K (L. sakei) broth

5: L. sakei + fermentation broth of S. cerevisiae mixed with Saccharomyces

The present invention relates to an anti-ulcer composition comprising a fermentation broth of rice or glutinous rice sugar as an active ingredient, and a method for preparing the same. More specifically, the fermentation broth obtained by saccharifying rice or glutinous rice and fermenting with lactic acid bacteria and / or yeast is an active ingredient It relates to an anti-ulcer composition contained therein and a method for producing the same.

The stomach is an organ that stores food coming in through the esophagus, breaks it down easily for digestion, and regulates the feeding of food into the duodenum for efficient digestion and absorption. The stomach secretes gastric acid, a strong acid, to digest food when it comes in. The mucosal protective layer prevents gastric mucosal damage caused by gastric acid. Inflammation occurs when gastric acid secretion is increased or gastric mucosal protective layer is damaged by various causes. When this inflammatory lesion is limited to the gastric mucosa, gastritis and gastric mucosa are formed when the ulcers form the submucosal tissue and muscle layer. Ulcers in the duodenum are also called duodenal ulcers, and stomach and duodenal ulcers are collectively referred to as peptic ulcers.

Such peptic ulcers are caused by aggression of attackers or weakening of defenders. Among the attack factors are gastric acid, anti-inflammatory agents, bacterial infections, etc., and the defense factors include mucus, cell regeneration, and alkali secretion. Recently, infection of bacteria called Helicobacter pyroli has been pointed out as an important cause (Watanabe et al., Gastroenterology, 115, 642 (1988)).

H. pylori is a curved gram-negative bacteria and in size here considered as a major factor in the 2 ~ 7 × 0.4 ~ 1.2μm degree of non-aerobic (microaerophilic) bacteria as gastritis, gastric ulcer, duodenal ulcer, etc. Digestive Diseases (Parsonnet et al., 1994, N Eng J Med , 330, 1267 ~ 1271) 65% of those infected with Helicobacter spp. Have been diagnosed with gastritis. 95% of patients are infected with this bacterium. In foreign countries, the infection rate of Helicobacter is about 20% in 20s and 50% in 50s.However, people in Korea are eating spicy foods and spicy and salty foods that stimulate the stomach. Helicobacter has a high incidence because of eating habits, and infection begins in infancy, and is about 50% at 5 years old, 80-90% at 10 years of age, and 90% at 20 years of age. Et al., 1990, Korean Society for Microbiology , 25: 475).

However, Helicobacter pylori is often resistant to antibiotics on the market, and because it is present in the lower gastric mucosa, it is not effectively exposed to antibiotics. Due to the low pH in the stomach, many conventional antibiotics lose their titers. This is difficult to use as a therapeutic.

On the other hand, elimination of Helicobacter Philo by tritherapy, including bismuth preparation, metronidazole and amoxicillin or tetracycline is used (Bell GD et al ., 1993, Scand). J Gastroenterol , 28: Suppl196: 7), which have limitations in use, such as poor drug compliance or adverse reactions (Rauws EAJ et al ., 1990, Lancet , 335: 1223).

Therefore, the present inventors have studied to develop an anti-ulcer composition showing antimicrobial activity against Helicobacter pylori, which is a safe natural substance having an anti-ulcer effect, which can be effectively applied to peptic ulcer, and is one of the main causes of peptic ulcer. Alternatively, a process of saccharifying glutinous rice using microorganisms has been developed, and an anti-ulcer composition comprising a fermentation broth obtained by fermenting the saccharate obtained therein with lactic acid bacteria and / or yeast as an active ingredient and a method of producing the same are completed.

Accordingly, it is an object of the present invention to provide an anti-ulcer composition containing a fermentation broth of rice or glutinous rice saccharide as an active ingredient.

It is another object of the present invention to provide a method for preparing an anti-ulcer composition containing a fermentation broth of rice or glutinous rice sugar as an active ingredient.

In order to achieve the above object, the present invention is an anti-ulcer composition comprising a fermentation broth obtained by saccharifying rice or glutinous rice using koji and enzyme and fermenting such a saccharified substance with lactic acid bacteria and / or yeast as an active ingredient. To provide.

In another aspect, the present invention provides a method for producing an anti-ulcer composition comprising the step of saccharifying rice or glutinous rice using koji and enzyme, fermenting the saccharity obtained in the saccharification step with lactic acid bacteria and / or yeast. do.

Hereinafter, the content of the present invention will be described in more detail.

The anti-ulcer composition of the present invention is characterized in that it contains a fermentation broth obtained by saccharifying rice or glutinous rice and fermented with lactic acid bacteria and / or yeast as an active ingredient, and the method of preparing the fermentation broth will be described as follows.

First step: rice or glutinous rice Saccharified  step

The saccharification step is performed by gelatinizing rice or glutinous rice and treating glycosylation enzyme.

Gelatinization of rice or glutinous rice may be performed by putting distilled water into rice or glutinous rice and treating it for 90 to 150 minutes at 60 to 90 ° C. At this time, in order to facilitate the gelatinization process, it is preferable to grind rice or glutinous rice into powder. Gelatinous liquid swells rice or glutinous rice and increases in viscosity to form a translucent colloidal material.

As the glycosylation enzyme, Cozy, α-amylase, β-amylase, glucoamylase and the like prepared by Aspergillus oryzae may be used. The saccharification step can be carried out at the temperature and time conditions optimized for each glycosylase, for example, the following process.

After adding α-amylase and reacting at 80 to 100 ° C. for 60 to 150 minutes, the Cozy and glucoamylase prepared by Aspergillus duckase may be added to react at 120 to 180 minutes at 50 to 75 ° C. to perform a saccharification step. .

At this time, if the reaction temperature is lower than the reaction temperature of the enzyme is lowered, the synthesis of the active ingredient is lowered, if higher than each reaction temperature, the stability of the enzyme is lowered, the synthesis of the active ingredient is lowered.

It is preferable that the temperature can be controlled while agitation is attached to the glycosylation group, and the pH is maintained at 4.0 to 5.0, preferably 4.3 to 4.5 at the time of saccharification in order to provide the optimum pH of the enzyme.

Second step: Sugars  Fermentation with lactic acid bacteria and / or yeast

The fermentation step may be carried out for 7 to 21 days at 10 ~ 20 ℃ temperature by inoculating the lactic acid bacteria and / or yeast strain of the glycosylated in the saccharification step obtained in the saccharification step. Saccharides can be used for fermentation after removing solids to facilitate fermentation temperature control. Removal of solids is possible, for example, by centrifugation using a conventional centrifuge to obtain supernatant.

As the lactic acid bacteria used for fermentation, known strains widely used in the food industry may be used. Examples of such strains include Lactobacillus acidophilus , Lactobacillus bulgaricus , Lactobacillus casei , Lactobacillus plantarum , Lactobacillus plantarum , and Lactobacillus delbruus delbrue del leuvi ) , Lactobacillus johnsonii , Lactobacillus rhamnosus , Lactobacillus sakei , Streptococcus thermophilus , Streptococcus piumium , Streptococcus pythium Bifidobacterium bifidum ) , Bifidobacterium Infantis infantis), ronggeom Bifidobacterium (Bifidobacterium longum), Peddie Oh Caucus pen Tosa three mouse (Pediococcus pentosaceus), current Kono Stock mesen teroyi Death (Leuconostoc mesenteroides ). In particular, it is preferable to use the microorganisms of the genus Lactobacillus, most preferably Lactobacillus rhamnosus, Lactobacillus sakei.

Yeast may use general brewing yeast or functional black yeast. Examples of such strains are Saccharomyces cerevisiae ), Saccharomyces sakei ) and Xanthophyllomyces dendrorhous , and Saccharomyces cerevisiae is preferably used.

The lactic acid bacteria and yeast may be used only one strain, it is possible to use a mixed microorganism mixed with a combination of several lactic acid bacteria and / or yeast as a starter. When fermented using mixed microorganisms, the beneficial effect each microorganism exhibits simultaneously occurs.

In an embodiment of the present invention, yeast and / or lactic acid bacteria fermentation broth of rice or glutinous rice saccharin was prepared.

In the experimental example of the present invention, the antiulcer activity was measured using an animal gastric ulcer model to confirm the antiulcer effect of the composition of the present invention. As a result, it was found that the compositions of the present invention using the fermentation broth of glutinous rice sugar have an excellent anti-ulcer effect.

In another experimental example of the present invention, the anti-helicobacter activity was measured to confirm the anti-helicobacter effect of the composition of the present invention. When Helicobacter pylori was treated with the composition of the present invention, the Helicobacter pylori did not grow, and the composition of the present invention was found to have anti-helicobacter activity.

Therefore, the composition of the present invention has an anti-ulcer effect and anti-helicobacter effect can be effectively used to treat, prevent and relieve ulcers, it is possible to take without long-term side effects because often used natural substances ingested.

Accordingly, the present invention provides a pharmaceutical composition for the prevention or treatment of ulcers containing the composition as an active ingredient.

The pharmaceutical composition according to the present invention may include a pharmaceutically effective amount of a lump extract alone or may include one or more pharmaceutically acceptable carriers. As used herein, the term “pharmaceutically effective amount” refers to an amount that exhibits a higher response than the negative control, and preferably an amount sufficient to treat or prevent an ulcer.

Pharmaceutically effective amounts of the compositions according to the invention are 1500-2500 mg / day / kg body weight, preferably 2000-2300 mg / day / kg body weight. However, the pharmaceutically effective amount may be appropriately changed depending on various factors such as the disease and its severity, the patient's age, weight, health condition, sex, route of administration and duration of treatment.

As used herein, “pharmaceutically acceptable” means a non-toxic composition that, when administered to human beings, is physiologically acceptable and does not inhibit the action of the active ingredient and typically does not cause gastrointestinal disorders, allergic reactions such as dizziness or the like. Say Such carriers include all kinds of solvents, dispersion media, oil-in-water or water-in-oil emulsions, aqueous compositions, liposomes, microbeads and microsomes.

On the other hand, the pharmaceutical composition according to the present invention can be formulated with a suitable carrier depending on the route of administration. The route of administration of the pharmaceutical composition according to the present invention is not limited thereto, but may be administered orally or parenterally. Parenteral routes of administration include, for example, several routes such as transdermal, nasal, abdominal, muscle, subcutaneous or intravenous.

In the case of oral administration of the pharmaceutical composition of the present invention, the pharmaceutical composition of the present invention is prepared in powder, granule, tablet, pill, dragee, capsule, liquid, gel according to a method known in the art together with a suitable oral carrier. , Syrups, suspensions, wafers and the like. Examples of suitable carriers include sugars, including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol and starch, cellulose, starch including corn starch, wheat starch, rice starch and potato starch, and the like. Fillers such as cellulose, gelatin, polyvinylpyrrolidone, and the like, including methyl cellulose, sodium carboxymethylcellulose, hydroxypropylmethyl-cellulose, and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid or sodium alginate and the like may optionally be added as a disintegrant. Furthermore, the pharmaceutical composition may further include an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, a preservative, and the like.

In addition, the pharmaceutical compositions according to the invention may comprise one or more buffers (e.g. saline or PBS), carbohydrates (e.g. glucose, mannose, sucrose or dextran), antioxidants, bacteriostatic agents, chelating agents (Eg, EDTA or glutathione), adjuvants (eg, aluminum hydroxide), suspending agents, thickening agents, and / or preservatives.

In addition, the pharmaceutical compositions of the present invention may be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.

Furthermore, the composition according to the present invention may be provided in the form of a food composition for the purpose of preventing or ameliorating ulcers. The food composition of the present invention includes all forms such as functional foods, nutritional supplements, health foods and food additives. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.

For example, as a health food, the composition itself of the present invention may be prepared in the form of tea, juice and drink for drinking, or granulated, encapsulated and powdered. In addition, it can be prepared in the form of a mixed composition by mixing with the composition of the present invention and known active ingredients known to improve and prevent ulcers.

In addition, functional foods include beverages (including alcoholic beverages), fruits and processed foods (e.g. canned fruit, canned foods, jams, marmalade, etc.), fish, meat and processed foods (e.g. ham, sausage corned beef) Breads and noodles (e.g. udon, soba noodles, ramen, spaghetti, macaroni, etc.), fruit juices, various drinks, cookies, syrups, dairy products (e.g. butter, cheese), edible vegetable oils, margarine, vegetable protein , Retort foods, frozen foods, various seasonings (e.g., miso, soy sauce, sauce, etc.) may be added to the composition of the present invention.

In addition, in order to use the composition of the present invention in the form of a food additive, it can be prepared in powder or concentrate form.

Preferred content of the composition of the present invention in the food composition of the present invention may include about 3 to 5% by weight relative to the total weight of the food.

Below. The present invention will be described in detail by way of examples.

However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

EXAMPLES Preparation of Fermentation Solution of Rice and Glutinous Rice Sugars

In order to prepare a saccharin, the surface of ordinary rice or glutinous rice was washed with distilled water and then left to dry at room temperature. This was ground finely using a grinder to make fine powder (米粉) was used to prepare a saccharified.

1680 g of distilled water was added to 272 g of fine powder, and gelatinized while raising the temperature to 90 ° C., and 0.39 mg of α-amylase (Termamyl 120L, Novozyme) was added and reacted at 90 ° C. for 90 minutes. Then, 48 g of Cozy made with Aspergillus oryzae and 0.39 mg of glucoamylase (Spirizyme, Novozyme) were placed in a saccharification container and reacted at 60 ° C. for 150 minutes to prepare a saccharified product, which was 15 brix. Distilled water was added.

Lactobacillus rhamnosus , Lactobacillus sakei , Saccharomyces cerevisiae , Lactobacillus sakei and Lactobacillus sakei Visier ( Saccharomyces cerevisiae ) was inoculated at 1% by weight and cultured at 15 ° C. for 15 days. The fermentation broth was crushed cells for 30 minutes at 30 ° C with 50% sonic at 30 ° C by ultrasonic (sonics, vibra cell ^TM ), centrifuged at 10000rpm for 10 minutes, and then only the supernatant was obtained. 2 to 5 times concentrated. At this time, the degree of fermentation was based on alcohol concentration (6%) in the case of fermentation using yeast, and each fermentation broth was standardized and concentrated based on the acidity (0.3%) of fermentation broth in the case of fermentation using lactic acid bacteria.

Experimental Example 1 Confirmation of the Anti-ulcer Effect of the Composition of the Present Invention

In order to confirm the antiulcer efficacy of the composition of the present invention, the antiulcer activity was tested using an animal gastric ulcer model.

First, 0.3ml of each fermentation broth of the present invention was orally administered to Sprague-Dawley-based 7-week-old rats (Sampacobio Korea, Korea) of about 250g body weight, and 30ml after 1ml of ethanol (95%, Merck). Gastric ulcer was induced. At this time, as a control group, rats to which ethanol was administered after administration of distilled water or glutinous rice saccharin instead of the composition of the present invention were used.

1.5 hours after the administration of ethanol, the rats were opened and stomach was extracted. After the incision was made, the inner surface of the incised stomach was photographed to measure the area of the ulceration area with a stereomicroscope. The measurement results are expressed in ulceration index, which is the percentage of the area of ulcer area relative to the total area of gastric mucosa.

Ulcer index measurement results for the experimental group and the control group not administered the glutinous rice fermentation broth prepared in Example 2 are shown in Table 1.

division Experimental group Control Lactobacillus rhamnosus Lactobacillus sakei Saccharomyces cerevisiae Lactobacillus sakei and Saccharomyces cerevisiae Glutinous rice sugar Distilled water Ulcer Index 7.3 6.8 12.5 5.1 15.2 71.0

Glutinous rice fermentation broth fermented with Lactobacillus rhamnosus in rats, respectively. Glutinous rice fermented with Lactobacillus sakei, glutinous rice fermented with Saccharomyces cerevisiae, and glutinous rice fermented with Lactobacillus sakei and Saccharomyces cerevisiae orally, followed by ethanol administration The average gastric ulcer index (gastric ulcer area / gastric mucosa x 100) was 7.3, 6.8, 12.5, and 5.1, respectively. , 71.0).

As can be seen from the above results, the composition of the present invention was shown to have an excellent anti-ulcer effect of preventing or healing artificially induced ulcers in white rats.

On the other hand, instead of orally administering each fermentation broth prepared in Example 2 to the rats, each was freely ingested for 3 days, except that gastric ulcer was the same as above, and the same as the above case.

On the other hand, instead of orally administering each fermentation broth prepared in Example 2 to rats, the concentration (0-25mg) was changed freely for 3 days. As the concentration of fermentation broth increased, the antiulcer effect was gradually increased.

Experimental Example 2 Confirmation of Anti-Helicobacter Activity of the Composition of the Present Invention

Helicobacter pylori (ATCC43504) was sterilized in sterile Brucellar agar (Difco, USA) with 5% bovine calf serum (Gibco, USA), vancomycin (10 mg / L), and polymyxin B ( polymyxin B, 5mg / L), trimetoprim (5mg / L) and amphotericin B (amphotericin B, 2mg / L) were added to the culture medium. Cultivation was done in an incubator at 37 ° C., 10% CO 2, 95% humidity.

To measure anti-Helicobacter activity, sterile Brucella agar was inoculated with 1% (v / v) of a culture of Helicobacter Philophyll and plates were used. The fermentation broth and glutinous rice sugar of the present invention were inoculated on 100 μl, respectively, and incubated for 72 hours, and then the size of the transparent ring was measured.

As a result of the measurement, the control group (untreated group) did not produce a transparent ring that inhibits the growth of Helicobacter, and the glutinous rice fermentation broth fermented with Lactobacillus rhamnosus. Glutinous rice fermented with Lactobacillus sakei, glutinous rice fermented with Saccharomyces cerevisiae, and glutinous rice fermented with Lactobacillus sakei and Saccharomyces cerevisiae, respectively, 10 mm, 3 mm, 1.5 It was found that a transparent ring of mm and 5 mm was formed. Therefore, the composition of the present invention was found to have anti-helicobacter activity.

As described above, the composition of the present invention includes a fermentation broth obtained by fermenting saccharified rice or glutinous rice using lactic acid bacteria and / or yeast, and thus has an anti-ulcer effect and an anti-helicobacter effect, and thus has an excellent healing effect against ulcers. It has a preventive effect. Therefore, the food composition of the present invention can be used not only for the purpose of treating and preventing ulcers, but also as a functional food having an anti-ulcer effect, in particular, a mainstream material.

Claims (8)

An anti-ulcer composition comprising a fermentation broth fermented with at least one selected from the group consisting of lactic acid bacteria and yeasts, a saccharified glycosylated rice or glutinous rice as an active ingredient. The anti-ulcer composition according to claim 1, wherein the glycosylase is at least one selected from the group consisting of koji, α-amylase and glucoamylase. The method of claim 1, wherein the lactic acid bacteria is Lactobacillus rhamnosus (Lactobacillus rhamnosus), Lactobacillus sakei (Lactobacillus sakei), Lactobacillus ashdophilus (Lactobacillus acidophilus), Lactobacillus Bulgaricus (Lactobacillus bulgaricus), Lactobacillus casei (Lactobacillus casei), Lactobacillus plantar room (Lactobacillus plantarum), Lactobacillus del Bruieki (Lactobacillus delbruekii ), Lactobacillus Johnson, (Lactobacillus johnsonii), Streptococcus thermophilus (Streptococcus thermophilus), Streptococcus fish (Streptococcus pythium), Bifidobacterium Bifidem (Bifidobacterium bifidum), Bifidobacterium infantis (Bifidobacterium infantis), Bifidobacterium longgum (Bifidobacterium longum), Pediococcus pentosaceus (Pediococcus pentosaceus), Leukonostock Mesenteroides (Leuconostoc mesenteroidesAnti-ulcer composition, characterized in that at least one selected from the group consisting of. The method of claim 1, wherein the yeast is Saccharomyces cerevisiae (Saccharomyces cerevisiae), Saccharomyces sakei (Saccharomyces sakei), Xanthophyllomyces dendrorose (Xanthophyllomyces dendrorhousAnti-ulcer composition, characterized in that at least one selected from the group consisting of. (a) saccharifying rice or glutinous rice with glycosylation enzyme; (b) a method of producing an anti-ulcer composition, comprising the step of fermenting the sugars prepared in step (a) to at least one selected from the group consisting of lactic acid bacteria and yeast. The method according to claim 5, wherein the glycosylase is at least one selected from the group consisting of koji, α-amylase and glucoamylase. The method of claim 5, wherein the lactic acid bacteria is Lactobacillus rhamnosus (Lactobacillus rhamnosus), Lactobacillus sakei (Lactobacillus sakei), Lactobacillus ashdophilus (Lactobacillus acidophilus), Lactobacillus Bulgaricus (Lactobacillus bulgaricus), Lactobacillus casei (Lactobacillus casei), Lactobacillus plantar room (Lactobacillus plantarum), Lactobacillus del Bruieki (Lactobacillus delbruekii ), Lactobacillus Johnson, (Lactobacillus johnsonii), Streptococcus thermophilus (Streptococcus thermophilus), Streptococcus fish (Streptococcus pythium), Bifidobacterium Bifidem (Bifidobacterium bifidum), Bifidobacterium infantis (Bifidobacterium infantis), Bifidobacterium longgum (Bifidobacterium longum), Pediococcus pentosaceus (Pediococcus pentosaceus), Leukonostock Mesenteroides (Leuconostoc mesenteroidesMethod for producing at least one selected from the group consisting of. According to claim 5, wherein the yeast Saccharomyces cerevisiae ( Saccharomyces cerevisiae ), Saccharomyces Saccharomyces sakei ), Xanthophyllomyces dendrorhous ) is one or more selected from the group consisting of a manufacturing method.

Images